Compound Therapeutics develops protein therapeutics targeted towards inflammation, autoimmunity, cancer, and infections disease. These are developed on their PROfusion platform which they acquired from Phylos

History:

Compound Therapeutics changed their name to Adnexus Therapeutics in 2006. They were acquired by Bristol-Meyers Squibb in 2007 where they now act as a subsidiary.

Acquisitions
Phylos (2004)

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Northeast

Research Focus:
Proteomics Disease Therapeutics-Research

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: